{
    "clinical_study": {
        "@rank": "149495", 
        "arm_group": [
            {
                "arm_group_label": "Test 1", 
                "arm_group_type": "Experimental", 
                "description": "fixed dose combination tablet"
            }, 
            {
                "arm_group_label": "Reference 1", 
                "arm_group_type": "Active Comparator", 
                "description": "empagliflozin tablets and metformin tablet"
            }, 
            {
                "arm_group_label": "Test 2", 
                "arm_group_type": "Experimental", 
                "description": "fixed dose combination tablet"
            }, 
            {
                "arm_group_label": "Reference 2", 
                "arm_group_type": "Active Comparator", 
                "description": "empagliflozin tablet and metformin tablet"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this trial is to establish bioequivalence of two FDC tablets and\n      the single tablets when administered together after a high fat high caloric meal."
        }, 
        "brief_title": "Demonstration of Bioequivalence of Empagliflozin and Metformin Given in One Tablet Compared to the Intake of Single Tablets", 
        "completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n        1. Healthy male and female subjects\n\n        Exclusion criteria:\n\n        1. Any relevant deviation from healthy conditions"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 22, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01672788", 
            "org_study_id": "1276.7", 
            "secondary_id": "2012-002277-65"
        }, 
        "intervention": [
            {
                "arm_group_label": "Reference 1", 
                "description": "empagliflozin tablets and metformin tablet", 
                "intervention_name": "Empagliflozin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Test 2", 
                "description": "fixed dose combination tablet (low)", 
                "intervention_name": "Empagliflozin + Metformin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Reference 1", 
                "description": "empagliflozin tablets and metformin tablet", 
                "intervention_name": "Metformin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Reference 2", 
                "description": "empagliflozin tablet and metformin tablet", 
                "intervention_name": "Metformin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Test 1", 
                "description": "fixed dose combination tablet (low)", 
                "intervention_name": "Empagliflozin + Metformin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Reference 2", 
                "description": "empagliflozin tablet and metformin tablet", 
                "intervention_name": "Empagliflozin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Metformin"
        }, 
        "lastchanged_date": "April 3, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Biberach", 
                    "country": "Germany"
                }, 
                "name": "1276.7.1 Boehringer Ingelheim Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "4", 
        "official_title": "Bioequivalence of Empagliflozin/Metformin (850 mg) Fixed Dose Combination Tablets Compared to Single Tablets Administered Together in Healthy Male and Female Volunteers Under Fed Conditions (an Open-label, Randomised, Single-dose, Four-way Crossover Study)", 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "AUC0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)", 
                "safety_issue": "No", 
                "time_frame": "up to 72 hours after drug intake"
            }, 
            {
                "measure": "Cmax (maximum measured concentration of the analyte in plasma)", 
                "safety_issue": "No", 
                "time_frame": "up to 72 hours after drug intake"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01672788"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point)", 
            "safety_issue": "No", 
            "time_frame": "up to 72 hours after drug intake"
        }, 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}